NASDAQ: PASGPassage Bio Inc Stock
$4.68+0.10 (+2.18%)
Updated Jul 2, 2026
PASG Price
$4.68
Fair Value Price
$7.03
Market Cap
$15.01M
52 Week Low
$3.30
52 Week High
$20.00
P/E
-0.39x
P/B
1.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.1
Operating Cash Flow
-$31M
Beta
1.69
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PASG Overview
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PASG's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PASG
Ranked#372 of 463
Ranked#372 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important PASG news, forecast changes, insider trades & much more!
PASG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PASG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PASG ($4.68) is undervalued by 33.39% relative to our estimate of its Fair Value price of $7.03 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PASG ($4.68) is significantly undervalued by 33.39% relative to our estimate of its Fair Value price of $7.03 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PASG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PASG due diligence checks available for Premium users.
Valuation
PASG fair value
Fair Value of PASG stock based on Discounted Cash Flow (DCF)
Price
$4.68
Fair Value
$7.03
Undervalued by
33.39%
PASG ($4.68) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PASG ($4.68) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PASG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PASG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.39x
Industry
17.59x
Market
8.54x
PASG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
5.6x
PASG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PASG's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.6M
Profit Margin
0%
PASG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$36.5M
Liabilities
$24.7M
Debt to equity
2.1
PASG's short-term assets ($34.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PASG's short-term assets ($34.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PASG's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PASG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.0M
Investing
$20.0k
Financing
$0.0
PASG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PASG vs Biotech Stocks
Passage Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.